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Opioids selective for the G protein-coupled mu opioid receptor (MOR) produce potent
analgesia and euphoria. Heroin, a synthetic opioid, is considered one of the most addictive
substances, and the recent exponential rise in opioid addiction and overdose deaths
has made treatment development a national public health priority. Existing medications
(methadone, buprenorphine, and naltrexone), when combined with psychosocial therapies,
have proven efﬁcacy in reducing aspects of opioid addiction. Unfortunately, these medica-
tions have critical limitations including those associated with opioid agonist therapies (e.g.,
sustained physiological dependence and opioid withdrawal leading to high relapse rates
upon discontinuation), non-adherence to daily dosing, and non-renewal of monthly injection
with extended-release naltrexone. Furthermore, current medications fail to ameliorate
key aspects of addiction such as powerful conditioned associations that trigger relapse
(e.g., cues, stress, the drug itself). Thus, there is a need for developing novel treatments
that target neural processes corrupted with chronic opioid use. This requires a basic
understanding of molecular and cellular mechanisms underlying effects of opioids on
synaptic transmission and plasticity within reward-related neural circuits. The focus of
this review is to discuss how crosstalk between MOR-associated G protein signaling and
glutamatergic neurotransmission leads to immediate and long-term effects on emotional
states (e.g., euphoria, depression) and motivated behavior (e.g., drug-seeking, relapse).
Our goal is to integrate ﬁndings on how opioids modulate synaptic release of glutamate
and postsynaptic transmission via α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
and N -methyl-D-aspartate receptors in the nucleus accumbens and ventral tegmental area
with the clinical (neurobehavioral) progression of opioid dependence, as well as to identify
gaps in knowledge that can be addressed in future studies.
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INTRODUCTION
Opioids comprise a class of endogenous, naturally occurring
and synthetic compounds that bind to and activate one of three
known opioid receptors: mu, delta, and kappa (MOR, DOR,
KOR, respectively). All opioids possess analgesic properties, which
humans have taken advantage of for thousands of years. They
also have profound effects on physiology and mood that depend
on the speciﬁc opioid receptor and site of action in the brain.
Opiates, a subclass of opioids that are natural derivatives of
the opium plant, papaver somniferum, include morphine and
codeine, which are the two major metabolites of heroin. These
compounds primarily activate MORs to produce euphoria that
can motivate repeated self-administration, produce tolerance,
dependence, and ultimately opioid addiction. One percent of all
Americans meet criteria for having an opioid use disorder (OUD);
heroin use has doubled since 2007, and 2% of all Americans
age 12 and older report misuse of a prescription opioid anal-
gesic within the past 30 days (NSDUH, 2013). In 2008, there
were 15,000 accidental overdose deaths related to prescription opi-
oid use alone (Center for Disease Control) and opioid analgesics
are second only to marijuana as the ﬁrst illicit drug reported
taken by 1.9 million youth and older adult Americans (NSDUH,
2013). The partial MOR agonist buprenorphine combined with
the diversion-preventing opioid receptor antagonist naloxone has
been partially successful in engaging youth and adults with OUD
into abstinence-focused treatment (Fudala et al., 2003; Mattick
et al., 2008; Woody et al., 2008; Weiss et al., 2011). However, con-
trolled data on longer-term outcomes is lacking and patients
taking agonist therapies (e.g. the long-lasting, full MOR ago-
nist methadone and buprenorphine) have high rates of relapse
(>75%) upon medication withdrawal (Woody et al., 2008; Weiss
et al., 2011).
In fact, the treatment course of OUD is primarily chal-
lenged by the experience of the opioid withdrawal syndrome
(OWS), which is characterized by both a typical physical syn-
drome occurring acutely (24–48 h post-withdrawal) and also by
an affective/cognitive syndrome of dysphoria, anxiety, irritability,
and preoccupation with cravings to use opioids (Kreek and Koob,
1998). These affective withdrawal symptoms occur acutely, but
they frequently have a protracted course in humans (Dole et al.,
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1966; Martin and Jasinski, 1969; see Table 1). Acute and protracted
OWS is observed in controlled studies and in clinical practice to
precipitate resumed opioid use; this is not only true for those ﬁrst
entering treatment and inexperienced in recovery practices but
also true for those in longer-term recovery on agonist therapy who
experience OWS during attempts to discontinue agonist therapy
(Magura and Rosenblum, 2001; Woody et al., 2008; Weiss et al.,
2011). Therefore, there is a great need to develop newer, medical
therapies that are not pharmacologically based on opioids them-
selves to assist peoplewithOUD in toleratingOWSwithout relapse
to opioid use.
The affective/cognitive components of OWS may be the
most important target for drug development, since non-opioid
medications (e.g., adrenergic antagonists, anti-emetics, sedative-
hypnotics) already exist and are widely applied to treat aspects
of the physical syndrome. Research in rats demonstrates that
naloxone-induced heightened acoustic startle, a pre-clinical proxy
for anxiety sensitivity, persists up to 80 days following a single
administration of morphine, whereas naloxone-induced condi-
tioned place aversion is not seen after 20 days (Rothwell et al.,
2012), suggesting that anxiety may be one of the most persis-
tent protracted symptoms of the OWS. In addition, one clinical
study in prescription opioid-dependent individuals suggests that
when patients are blinded to buprenorphine taper schedules, their
success rates in moving through opioid withdrawal to achieve sus-
tained opioid abstinence may be improved (Sigmon et al., 2013).
This could reﬂect a signiﬁcant component of anticipatory anxi-
ety about OWS under conditions where individuals are aware of
forced reduction.
In order to most successfully treat affective/cognitive com-
ponents of the OWS, it is imperative to understand how the
normal brain processes rewarding and aversive stimuli to mod-
ulate behavior, and how opioids subsequently act to change
behavior. Excitatory glutamatergic neurotransmission provides a
basis for communication between neurons that enables behavior.
Table 1 | Symptoms of unmedicated abstinence in heroin-dependent
men*.
Days of abstinence
Day 3 Day 10 Day 30
• Severe anxiety • Moderate anxiety • Mild anxiety
• Moderate depression • Subclinical depression • Mild depressive
symptoms
• Highest craving • Moderate craving • Milder craving
• Nasal discharge • Nasal discharge • Nasal discharge
• Mydriasis
• Abdominal pain
• Diarrhea
• Vomiting
*Based on results of two studies reported by Li et al. (2009) and Shi et al. (2009);
anxiety measured by the Hamilton Anxiety Scale (HAM-A), depression by the
Beck Depression Inventory (BDI).
Depending on the neural circuits activated, behavior can refer
to anticipated stimuli, emotional response, learning (stimulus-
response), or action – all of which become dysfunctional with
addiction. The goal of this review is to present and syn-
thesize the current state of knowledge on how activation of
MORs modulates glutamatergic neurotransmission through α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
and N-methyl-D-aspartate (NMDA) receptors. We will focus on
MOR–glutamate interactions within the mesolimbic dopamine
system, a key neural substrate for the affective consequences
of acute and chronic opioids. The basic pharmacology, neu-
roanatomical localization, and physiology of MORs have beenwell
studied in in vitro systems, animal models, and clinical research,
and there are numerous comprehensive reviews describing these
ﬁndings (Law et al., 2000; Williams et al., 2001, 2013; Shalev et al.,
2002; Waldhoer et al., 2004; Bailey and Connor, 2005; Pasternak,
2012).
MOR DISTRIBUTION AND ACTIONS
Mu opioid receptors are expressed throughout the brain. Several
comprehensive studies have been published in which MOR bind-
ing sites are mapped (Mansour et al., 1988, 1994; Le Merrer et al.,
2009). MORs are generally perisynaptic: they can be localized
postsynaptically on dendrites and cell bodies where they regulate
neuronal excitability and transduce receptor activation to down-
stream signal transductionpathways, and they can also be localized
presynaptically on axon terminals where they inhibit neurotrans-
mitter release via activation of K+ conductance and/or inhibition
of Ca2+ conductance (Williams et al., 2001). The cellular and neu-
roanatomical distribution of MORs is critical for understanding
the neural circuits involved in the initiation of opiate action and
subsequent plasticity with chronic drug use.
In the context of opiate dependence and withdrawal, several
key neuroanatomical substrates have been identiﬁed, in par-
ticular the reciprocal connections within the limbic subcircuit
of corticostriatal circuitry: GABAergic neurons of the nucleus
accumbens (NAc), dopaminergic neurons of the ventral tegmental
area (VTA), and glutamatergic neurons of the prefrontal cor-
tex (PFC). Importantly, these regions contribute to acute opiate
reward, dependence, tolerance, somatic and affective signs of
withdrawal, and relapse (Wise, 1989; Stinus et al., 1990; Harris
and Aston-Jones, 1994; Bonci and Williams, 1997; LaLumiere and
Kalivas, 2008; Chartoff et al., 2009; Shen and Kalivas, 2013). Rats
will self-administer opiates directly into the VTA (Bozarth and
Wise, 1983; Devine and Wise, 1994), which contains dopamin-
ergic cell bodies, and into the ventral striatum NAc (Olds, 1982),
which receives dopaminergic input from theVTA.Acutemorphine
increases dopamine release in the NAc (Di Chiara and Imperato,
1988b; Johnson and North, 1992) by inhibiting GABAergic neu-
rons in the VTA and rostromedial tegmental nucleus (RMTg) that
synapse on dopaminergic neurons (Tepper et al., 1995; Jalabert
et al., 2011). Morphine dependence – characterized by physical
and psychological withdrawal signs – is mediated by several brain
regions, with the locus coeruleus and periaqueductal gray (PAG)
regionmost sensitive to naloxone-precipitated somaticwithdrawal
symptoms (Koob et al., 1992). The mesolimbic system is also
important for morphine dependence, with a key role in affective
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signs of withdrawal: microinjections of naloxone into the NAc
causes conditioned place aversions (Koob et al., 1992), and admin-
istration of a dopamineD2-like, but not aD1-like, receptor agonist
directly into the NAc attenuates somatic withdrawal signs (Harris
and Aston-Jones, 1994). Also, dopamine release is decreased in
the NAc during morphine withdrawal (Rossetti et al., 1992; Diana
et al., 1995; Bonci and Williams, 1997), suggesting that the NAc
may mediate certain aspects of morphine dependence. Other key
brain regions important for opiate dependence include, but are
not limited to, the amygdala, hippocampus, and bed nucleus of
the stria terminalis (Mansour et al., 1995b; Gracy et al., 1997).
MOR ACTIVATION AND INTRACELLULAR SIGNALING
The physiological effects of morphine are absent in mice lacking
MORs (Matthes et al., 1996; Le Merrer et al., 2009), providing
strong support for the idea that MORs are necessary for the
clinically relevant effects of opiates. MORsbelong to theGprotein-
coupled receptor (GPCR) superfamily of seven transmembrane
receptors and the rhodopsin receptor subfamily and are linked
to pertussis toxin-sensitive inhibitory heterotrimeric guanosine
triphosphate-binding proteins (Gαi/Gαo). Overall, MORs, DORs,
and KORs are approximately 60% identical to each other (Chen
et al., 1993).
Upon MOR activation, G protein α and βγ subunits interact
with downstream effector systems to inhibit adenylyl cyclase and
voltage-gated Ca2+ channels and to stimulate G protein-activated
inwardly rectifying K+ channels (GIRKs) and phospholipase
Cβ (Childers, 1991; Waldhoer et al., 2004; Williams et al., 2013;
see Figures 1 and 2, Naïve condition, for depiction of MOR-
dependent signaling). In the presence of chronic morphine, a
compensatory increase in adenylyl cyclase activity occurs and
cAMP levels return to normal (see Figures 1 and 2, GABAer-
gic neurons in Naïve, Acute, and Chronic conditions). When
morphine is discontinued or withdrawal is pharmacologically pre-
cipitated, cAMP levels dramatically increase (see Figures 1 and 2,
GABAergic neurons in Withdrawal condition; Nestler and Agha-
janian, 1997; Williams et al., 2001). This phenomenon of early
inhibition and late positive regulation of adenylyl cyclase by mor-
phine has been demonstrated in several morphine-receptive brain
regions (Duman et al., 1988; Nestler andTallman,1988; Terwilliger
et al., 1991; Van Vliet et al., 1991; Self et al., 1995; Shaw-Lutchman
et al., 2002). Upregulation of the cAMP pathway observed during
morphine withdrawal activates cAMP-dependent protein kinase
A (PKA; Chartoff et al., 2003a,b, 2006). Interestingly, it has been
reported that the increase in adenylyl cyclase activity may itself
result in a decrease in transcript levels of particular cyclases in the
striatum (Spijker et al., 2004).
Protein kinase A phosphorylates and activates numerous sub-
strates, including the transcription factor cAMP response element
binding protein (CREB) and the AMPA receptor (AMPAR)
subunit GluR1 (Figure 1, Withdrawal condition; Figure 3; Kon-
radi et al., 1994; Chartoff et al., 2003b, 2006; Mangiavacchi and
Wolf, 2004). Optimal PKA-mediated increases in CREB and
GluR1 signaling requires NMDA receptor (NMDAR) activation
(Konradi et al., 1996; Wolf, 2010), providing early evidence
for crosstalk between MORs and glutamatergic transmission.
It is through these actions that morphine and heroin may
ultimately modulate fast excitatory transmission via AMPAR and
NMDAR.
GLUTAMATERGIC NEUROTRANSMISSION
The classic view of glutamate action comprises presynaptic release
of glutamate, binding to postsynaptic ionotropic receptors, and
clearance of glutamate by Na+-dependent glutamate transporters
(Anggono and Huganir, 2012). Layered upon this are the more
recently discovered inﬂuences of glial-derived glutamate release
and uptake and extrasynaptic mGluRs on excitatory synap-
tic transmission and plasticity (Kalivas et al., 2009). Although
this review focuses on MOR-mediated modulation of AMPAR
and NMDAR-mediated glutamatergic transmission, it is essen-
tial to understand that glutamate homeostasis (regulation of
synaptic and perisynaptic extracellular glutamate levels) requires
ionotropic and metabotropic (mGluR) receptors as well as a del-
icate balance between glial and synaptic glutamate release and
elimination. Comprehensive reviews of glutamate homeostasis in
the context of drug addiction are available (Kalivas, 2009; Kalivas
et al., 2009).
AMPA RECEPTORS
AMPARs are a subgroup of ionotropic glutamate receptors found
at most excitatory synapses, are activated at resting membrane
potential, and are considered the primary postsynaptic mediators
of glutamate transmission in the NAc (Cherubini et al., 1988).
AMPARs comprise four subunits (GluR1–4) that assemble in
various combinations to form tetramers (Seeburg, 1993; Holl-
mann and Heinemann, 1994; Dingledine et al., 1999). GluR1–4
share ∼70% sequence homology and differ primarily due to post-
transcriptional modiﬁcations, which confer unique properties to
the subunits. For example, the GluR2 transcript undergoes RNA
editing such that a glutamine residue in the channel-forming seg-
ment of the receptor is converted to an arginine (Sommer et al.,
1991). This renders GluR2-containing AMPARs impermeable to
Ca2+ (Burnashev et al., 1992). Given that AMPARs exist primar-
ily as GluR1–2 and GluR2–3 populations (Wenthold et al., 1996),
most AMPARs gate Na+ but not Ca2+. However, synaptic activ-
ity – including in vivo experience – can shift the stoichiometry
of synaptic AMPAR subunit composition toward GluR2-lacking
receptors (Liu and Cull-Candy, 2000; Takahashi et al., 2003; Ju
et al., 2004; Clem and Barth, 2006), and increasing GluR1 expres-
sion favors formation of GluR1-homomeric AMPARs that allow
Ca2+ ﬂux (Hollmann et al., 1991).
Trafﬁcking of AMPARs into and out of synapses determines
the level of excitatory synaptic strength and is a major mechanism
of plasticity underlying learning (Malinow and Malenka, 2002).
AMPARs can be endocytosed and exocytosed into perisynaptic
regions, and they can also be shuttled laterally along the surface
of the neuronal membrane between synaptic and extrasynaptic
compartments (Heine et al., 2008). A host of AMPAR auxiliary
subunits such as transmembrane AMPAR regulatory proteins
(TARPs), Cornichon proteins, Neuropilin, and Tolloid-like pro-
teins (Netos) are necessary for the dynamics of AMPAR subcellular
localization (Straub and Tomita, 2012). Heteromers containing
GluR2–3 subunits are constitutively recycled and maintain basal
AMPAR transmission, whereas heteromers containing GluR1–2
www.frontiersin.org May 2014 | Volume 5 | Article 116 | 3
Chartoff and Connery MOR–glutamate crosstalk in mesolimbic system
FIGURE 1 | Interactions between MOR and glutamatergic
neurotransmission in the nucleus accumbens (NAc). MORs are coupled
to inhibitory Gα i proteins and are found on glutamatergic and GABAergic
terminals and postsynaptically on (primarily) D1 receptor-expressing MSNs.
Acute opioids: Acute MOR activation in a naïve animal suppresses GABA and
glutamate release via inhibition of Ca2+ and activation of K+ conductances,
as well as inhibition of cAMP-mediated activation of non-selective cation
pacemaker currents (Ih). Postsynaptic NMDAR currents are augmented via
MOR-induced PKC activation. There is no known data on the acute,
immediate effects of opioids on AMPAR expression/localization/function in
naïve animals. Chronic opioids: Inhibitory effect of presynaptic mGluR2/3
receptors to inhibit glutamate release is increased during chronic opioid
treatment. Surface expression of GluR1 subunits is decreased on MSNs,
with no change in total AMPAR subunit expression. Levels and/or function of
the NR2A NMDAR subunit are increased, which may contribute to a
decreased afﬁnity for the co-agonist glycine and a decreased sensitivity to
PKC-mediated NMDAR activation. Opioid withdrawal : Extracellular glutamate
levels are increased, but synaptic transmission may be reduced via enhanced
mGluR2/3 autoreceptor function. GABA release is potentiated via augmented
cAMP and PKA pathways. NR2B surface expression is increased, perhaps
resulting in an increase in silent synapses devoid of AMPARs. Upregulated
cAMP and PKA signaling leads to increased P-GluR1Ser845, which may prime
AMPARs containing GluR1 at the plasma membrane to be shuttled to
synapse upon CaMKII activation. PfC, prefrontal cortex; VSub, ventral
subiculum; BlA, basolateral amygdala; MSN, medium spiny
neuron.
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FIGURE 2 | Interactions between MOR and glutamatergic
neurotransmission in the ventral tegmental area (VTA). Acute opioids:
Acute MOR activation in a naïve animal inhibits glutamatergic neurons via
arachidonic acid-dependent potentiation of voltage-dependent K+ channels.
GABA neurons are inhibited via G protein-mediated inhibition of Ca2+ and
activation of K+ conductances, and GABA release is decreased via
inhibition of cAMP-dependent facilitation of transmitter release. This leads
to disinhibition of dopamine neurons and increased somato-dendritic
dopamine release. Stimulatory dopamine D5 receptors on dopamine
neurons are activated and, in conjunction with CaMKII, facilitate increased
surface expression of GluR1 subunits. Chronic opioids: Dopamine ﬁring rate
remains elevated. Tolerance to inhibitory effects of MOR activation on
GABAergic neurons develops through compensatory upregulation of cAMP
systems, but dopamine neuron K+ channels are downregulated, enabling
increased basal ﬁring rate and burst activity of dopamine neurons. Total and
surface GluR1 is increased and NR1 subunits are increased. Opioid
withdrawal : Activity of GABA neurons is increased due to disinhibition of
Ca2+ channels and reduced activation of K+ channels. GABA release is
increased due to unmasking of upregulated cAMP systems. Extracellular
glutamate levels are increased, but inhibitory presynaptic GABAB and
mGluR2/3 receptor function is enhanced, leading to decreased synaptic
release of glutamate. RMTG, rostromedial tegmental nucleus; PPTg,
pedunculopontine tegmental nucleus, BNST, bed nucleus of the stria
terminalis; DA, dopamine.
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FIGURE 3 | Naloxone-precipitated morphine withdrawal increases
GluR1 phosphorylation in a PKA-dependent manner. (A) Rats were
subcutaneously implanted with morphine (2 × 75 mg) or placebo pellets
and returned to their home cages for 3 days in order for morphine
dependence to develop. Naloxone (0.0, 0.01, or 1.0 mg/kg, SC) was
injected and rats killed 30 min later. Brains were removed and frozen,
1-mm3 punches of the NAc were extracted, and P-GluR1Ser845 and β-actin
(protein loading control) were quantiﬁed on immunoblots. Data are
expressed as fold-induction of P-GluR1/actin levels relative to
non-dependent (placebo) rats treated with vehicle. *p < 0.05, **p < 0.01
compared to non-dependent (placebo) rats treated with vehicle. ∧p < 0.05
comparing groups under bar. N = 5–9 rats/group. Modiﬁed from Chartoff
et al. (2006). (B) PKA is required for super-induction of P-GluR1Ser845 during
naloxone-precipitated morphine withdrawal. Primary striatal cultures were
treated chronically with either vehicle or morphine (morph, 10 μM) for 6
days, followed by a 1.5-h treatment with vehicle [dimethylsulfoxide (DMSO)]
or the PKA inhibitor H89 (20 μM), followed by a 30-min incubation with
vehicle or naloxone (nal, 10 μM), and the dopamine D1 receptor agonist
SKF 82958 (SKF, 50 μM) for 15 min. The ratio of P-GluR1Ser845/actin was
determined for each sample and normalized to the control group ratio to
yield a fold induction. Data are plotted as the mean fold induction ± SEM.
*p < 0.05, **p < 0.01 compared with control. ∧p < 0.05, ∧∧p < 0.01
comparing groups designated by solid lines. N = 3 experiments with
treatments in triplicate (see Chartoff et al., 2003a for details).
subunits are delivered to synapses in a precisely regulated manner
and are critical for experience-dependent plasticity (see Mali-
now and Malenka, 2002). In the absence of activity, synapses
can be devoid of GluR1–2-containing AMPARs. PKA-mediated
phosphorylation of GluR1 at Ser845 (P-GluR1Ser845) enhances
channel conductance and open probability, and in combina-
tion with activity-dependent Ca2+ signaling (e.g. via NMDARs),
phosphorylation can drive GluR1 into synapses, which could
allow synaptic strengthening (Esteban et al., 2003). Importantly,
P-GluR1Ser845 is necessary but not sufﬁcient for trafﬁcking of
GluR1 subunits to synapses (e.g. Figure 2, Chronic condition).
In the NAc, this type of plasticity might involve convergence
of dopamine and glutamate inputs (Wolf et al., 2003): activa-
tion of postsynaptic D1 receptors induces P-GluR1Ser845 and
activation of NMDARs could allow synaptic delivery. Con-
versely, activation of AMPARs can lead to compensatory dephos-
phorylation of GluR1 and subsequent removal from synaptic
zones to intracellular vesicles (Beattie et al., 2000; Snyder et al.,
2003).
Synaptic scaling is a homeostatic form of plasticity in which
prolonged activity or lack of activity atAMPARs (∼1–3 days) leads
to compensatory decreases or increases, respectively, in synaptic
AMPAR levels (Turrigiano, 2008). This phenomenon is thought to
stabilize neuronal activity during periods of abnormal or patho-
logical activity, and may be highly relevant to addiction and drug
withdrawal.
NMDA RECEPTORS
NMDARs are a subgroup of ionotropic glutamate receptors found
throughout the brain that act – in concert with colocalized
AMPARs – as synaptic coincidence detectors to facilitate learn-
ing and memory (Tang et al., 1999; Citri and Malenka, 2008).
NMDARs exist as heterotetramers composed of two NR1 sub-
units and two subunits from the NR2 or NR3 family (Seeburg
et al., 1995). NR1 subunits are expressed ubiquitously in the brain,
whereas NR2 subunits are spatially localized (Dunah et al., 1999).
The basal forebrain (includes the NAc) is enriched for NR2A
and B, with a predominance of NR2B in NAc medium spiny
neurons (MSNs; Chen and Reiner, 1996; Kuppenbender et al.,
2000). NMDARs are unique in that they require both ligand
(glutamate) binding and membrane depolarization (to release
extracellular Mg2+ block) in order to be activated. Once acti-
vated, NMDARs conduct both Na+ and Ca2+, which results
in excitatory postsynaptic currents (EPSCs) with greater mag-
nitude and longer half-life than those from AMPARs that pass
only Na+. Perhaps most importantly, NMDAR activation engages
Ca2+-mediated signal transduction pathways that can have long-
lasting effects on gene expression, post-translationalmodiﬁcations
of proteins (e.g., phosphorylation), and voltage-gated ion chan-
nels (Hyman et al., 2006). In fact, Ca2+ inﬂux is required for
NMDAR-mediated long-term potentiation (LTP). The NR1 sub-
unit is essential for channel function whereas NR2 subunits
control channel gating and Mg2+ dependency (Monyer et al.,
1992).
Anatomical studies have shown that MORs and NMDARs
colocalize on single neurons in many brain regions, including
within the dorsal striatum and NAc shell (Trujillo, 2002; Glass
et al., 2009). More recently, immunoprecipitation analysis has
revealed that MORs can directly interact with NMDA NR1 sub-
units (Rodriguez-Munoz et al., 2012). This patternwas observed in
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the PAG, cerebral cortex, striatum, and dorsal spinal cord, suggest-
ing functional interactions between MOR and NR1 are important
for analgesic and affective responses to opioids.
The importance of NMDARs to opioid dependence and the
OWS may lie in the well established role of NMDARs in form-
ing associative memories via their ability to detect two coincident
synaptic events at the cellular level (i.e., LTP; long-term depres-
sion, LTD). This type of learning is thought to be important for
phenomena such as conditioned craving and conditioned with-
drawal, which are common in abstinent opiate addicts and are
major triggers of relapse. There is also evidence that NMDAR-
mediated plasticity is necessary for extinction of drug-associated
memories. Speciﬁcally, the NMDAR partial agonist, D-cycloserine
(DCS) facilitates extinction of morphine withdrawal-associated
place aversions in morphine-dependent rats (Myers and Car-
lezon,2010a) and extinction of cocaine-induced conditioned place
preferences (Botreau et al., 2006; Paolone et al., 2009).
Although NMDARs are classically thought of as a major sub-
strate for Hebbian learning, they can also have unconditioned
effects on reward and affective states. For example, rats will self-
administer competitive andnon-competitiveNMDARantagonists
directly into the NAc (Carlezon and Wise, 1996b), and NMDAR
antagonists potentiate brain stimulation reward (Carlezon and
Wise, 1996a). These ﬁndings suggest that a reduction in the over-
all excitability of neurons in the NAc (via NMDAR blockade)
and/or a reduction in intracellular Ca2+ signaling is sufﬁcient for
reward. It is likely that NMDAR-mediated increases in synaptic
strength (learning) and changes in affective state are not mutu-
ally exclusive processes. One can envision a scenario during drug
withdrawal in which the experience of an intense dysphoric state is
stamped into memory through NMDAR activation in select brain
regions. This idea will be discussed in more detail in the following
sections.
NUCLEUS ACCUMBENS
The NAc (ventral striatum) can be subdivided into multiple terri-
tories based on functional connectivity and neuronal phenotypes
(Zahm and Brog, 1992). The NAc core is a central portion of
the ventral striatum that surrounds the anterior commissure and
is a functional continuation of the neighboring dorsal striatum.
It has been shown to be particularly important for instrumen-
tal learning such as cue-induced reinstatement of drug seeking
(McFarland and Kalivas, 2001). The shell comprises the most
ventral and medial portions of the NAc, and has an important
role in drug reward, motivated behavior, behavioral sensitiza-
tion, and changes in affective state. In addition, subterritories
such as the rostral pole, cone and intermediate zone of the
NAc shell have been described (Zahm and Brog, 1992). A long-
standing conception is that the NAc is a “motivation to movement
interface” (Mogenson et al., 1980), and accumulating evidence
has conﬁrmed this idea by identifying the neural circuits that
loop from limbic and cognitive cortical regions to motor out-
put regions (Haber and Knutson, 2010). Thus, the NAc is a
key site for transference of motivational and emotional signals
to adaptive behavioral responses. Despite its long tenure as the
“reward center” of the brain, increasing evidence supports the
idea that the NAc is a bivalent structure that processes positive
and negative emotional stimuli into either approach or avoidance
behavior (Becerra et al., 2001; Reynolds and Berridge, 2002; Jensen
et al., 2003; Roitman et al., 2005; Carlezon and Thomas, 2009).
This has important ramiﬁcations for understanding addiction,
since drugs of abuse provide hyperbolic positive (drug “high”)
and negative (drug withdrawal, “crash”) emotional signals to the
NAc.
AFFERENTS
Consistent with the view that the NAc gates rewarding and aver-
sive stimuli and directs subsequent goal-directed behavior, NAc
afferents come from brain regions known to be important for
processing both positive and negative emotional stimuli, such as
the basolateral amygdala (Kelley et al., 1982) and for goal-directed
behavior, including the orbitofrontal cortex, insula, cingulate cor-
tex (Berendse et al., 1992), andmidline and intra-laminar thalamic
nuclei (Berendse and Groenewegen, 1990). In addition, the NAc
receives rich innervation from the ventral subiculum of the hip-
pocampus (Kelley and Domesick, 1982; Groenewegen et al., 1987),
which likely provides spatial and contextual information about
the stimuli (for review of NAc afferents, see Brog et al., 1993;
Sesack and Grace, 2010). The vast majority of NAc afferents
are glutamatergic and provide the excitatory drive necessary to
evoke behavior. The NAc also receives some inhibitory, GABAer-
gic inputs from the ventral pallidum and the VTA, as well as local
inhibitory connections from within the striatum (Brog et al., 1993;
Sesack and Grace, 2010). Layered on top of fast neurotransmis-
sion controlled by glutamate and GABA, the output of the NAc
is modulated by robust networks of neuropeptides, both intrin-
sic and extrinsic to the NAc. These include, but are not limited
to, orexin, dynorphin, enkephalin, substance P, and neurotensin
(Hokfelt et al., 2000). Finally, dopamine afferents from the VTA
provide an essential component of reward processing in the NAc.
Dopaminemodulates the general excitability of NAc neurons, thus
increasing or decreasing behavioral output based on the level of
emotional salience coded by the dopamine input (Koob, 1992;
Ikemoto and Panksepp, 1999; Wise, 2004).
INTRINSIC SIGNALING
Within the NAc, GABA-containing medium spiny output neu-
rons comprise the majority (∼90–95%) of neurons (Wilson and
Groves, 1980; Gerfen, 1992), with the remaining cells being either
GABAergic or cholinergic interneurons (Kawaguchi et al., 1995).
The function of MSNs depends on their particular inputs and out-
puts, but also on the phenotype of the MSN itself. Only recently
have researchers had the tools to begin to dissect the complex
microcircuitry of the NAc. As with the dorsal striatum,NAc MSNs
can be broadly divided into dopamineD1-like (includesD1 andD5
receptors) or dopamine D2-like (includes D2, D3, and D4) recep-
tor expressing circuits (Gerfen et al., 1990; Lobo, 2009). MSNs
express different constellations of neuropeptides, with dynorphin
often co-expressing with dopamine D1 receptors and enkephalin
with dopamine D2 receptors (Gerfen et al., 1990; Lobo, 2009). In
the NAc, MORs are expressed primarily by dynorphin- and D1
receptor-expressing cells (Georges et al., 1999).
Glutamate neurotransmission is kept under tight control:
too much or too little can have devastating effects (Kalivas,
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2009), whereas stimulus-dependent changes in glutamatergic
transmission are necessary for learning (Kauer and Malenka,
2007). Structurally, synaptic input to MSNs is arranged such
that glutamatergic afferents synapse on dendritic spines and
modulatory inputs such as dopamine make connections extra-
synaptically on dendritic shafts. This triad of spine, glutamate
synapse and dopamine synapse allows dopamine to modu-
late the general excitability of NAc neurons (Surmeier et al.,
2007; Sesack and Grace, 2010). Glutamatergic activation of
NAc MSNs is mediated primarily by AMPARs (Hu and White,
1996). Approximately 90% of AMPARs in the NAc are made
of GluR1 and GluR2 or GluR3 containing tetramers with only
about 6% being GluR1–3 complexes (Wolf, 2010; Reimers et al.,
2011). There is some evidence for a very small percentage
of AMPARs in the NAc to exist as GluR1 homomers. Func-
tionally, this implies that the vast majority of NAc AMPARs
conduct Na+ but not Ca2+, given that GluR2 renders AMPARs
impermeable to Ca2+. NMDARs play a critical role in tagging
connections that receive convergent glutamate and dopamine
inputs. For example, cortical excitation of selected MSNs in
the presence of dopamine would lead to an increase in synap-
tic strength in a two-step process: activation of postsynaptic
D1 receptors induces PKA-dependent P-GluR1Ser845 and activa-
tion of NMDARs facilitates synaptic delivery of GluR1 (Wolf,
2010).
EFFERENTS
The functional consequences of glutamate transmission in theNAc
are being elucidated: in general, NAc neurons are activated in
response to aversive stimuli and inhibited in response to reward-
ing stimuli (Peoples and West, 1996; Carelli, 2002; Roitman et al.,
2005). GABAergic MSNs from the NAc project to the ventral pal-
lidum, substantia nigra (SN), VTA, hypothalamus, and brainstem
(Haber et al., 1990). There is topographical organization such that
a medial (i.e., shell) to lateral (i.e., core/dorsal striatum) series of
projection loops allows emotion-based information from limbic-
associated structures to transfer to motor-related areas of the basal
ganglia (Haber et al., 2000). Within these spiraling loops, some
NAc outputs – particularly in the core – are functionally analo-
gous to the direct and indirect pathways described for the dorsal
striatum (Sesack and Grace, 2010). Activation of Gαs-coupled D1-
like receptors stimulates production of cAMP and tends to excite
MSNs that project directly back to the VTA and the ventral pal-
lidum (direct pathway), whereas activation of Gαi-coupledD2-like
receptors inhibits cAMP production and tends to inhibit MSNs
that selectively project to the ventral pallidum (indirect pathway;
Lu et al., 1998; Surmeier et al., 2007). Thus, cortical activation
of the direct pathway leads to disinhibition of motor circuits
that enable reward acquisition whereas activation of the indi-
rect pathway inhibits motor circuits that are maladaptive (Mink,
1996).
VENTRAL TEGMENTAL AREA
The VTA has been extensively studied for its role in reward and
addiction. Opioids are self-administered directly into the VTA
(Bozarth and Wise, 1981; Devine and Wise, 1994), while blockade
of VTA MORs suppresses heroin self-administration (Britt and
Wise, 1983). Intra-VTA morphine injections produce conditioned
place preferences (Bozarth, 1987), enhance the rewarding impact
of intracranial self-stimulation (Broekkamp et al., 1976), and rein-
state extinguished lever pressing for heroin (Stewart et al., 1984).
Dopamine neuronsmake up about 60–65%of the cells in theVTA,
with GABAergic (∼25%) and glutamatergic (up to 15%) neurons
making up the rest (Swanson, 1982; Nair-Roberts et al., 2008).
Most classes of drugs of abuse increase dopamine release in effer-
ent targets of theVTA, including theNAc (DiChiara and Imperato,
1988a). Comprehensive reviews of the role of VTA dopamine in
reward function and addiction have been published (Berridge and
Robinson, 1998; Wise, 2004; Fields et al., 2007; Ikemoto, 2007;
Wheeler and Carelli, 2009; Salamone and Correa, 2012), with the
emerging view that not only does dopamine mediate the positive
reinforcing effects of drugs but it is also instrumental in learning
how particular behaviors lead to reward or aversion (Volman et al.,
2013).
AFFERENTS
TheVTA is regulated by an integrated network of excitatory inputs
arising from the PFC, the pedunculopontine region (PPTg), the
laterodorsal tegmentum (LDTg), and the sub thalamic nucleus
(Grace et al., 2007). These connections are organized in the sense
that glutamatergic inputs from the medial PFC (mPFC) synapse
on dopamine neurons that project back to the mPFC but not on
those that project to the NAc (Carr and Sesack, 2000). The VTA
and the more caudal“tail”of theVTA (RMTg) receives GABAergic
input from the lateral habenula, NAc shell, and ventral pallidum
(Zahm and Heimer, 1990; Jhou et al., 2009). Importantly, the
RMTg provides tonic GABAergic inhibition of VTA dopamine
neurons that keeps them in a pacemaker-type ﬁring pattern in the
absence of stimulation (Bourdy and Barrot, 2012). The transition
from pacemaker-like ﬁring of dopamine neurons to burst ﬁring,
which is thought to represent a phasic dopamine response asso-
ciated with reward and reward-related cues, requires glutamate
input from the PPTg–LDT complex (Floresco et al., 2003; Lodge
and Grace, 2006; Grace et al., 2007).
INTRINSIC SIGNALING
GABA neurons of the VTA and RMTg express dense MOR mRNA
and immunoreactivity (Mansour et al., 1988, 1995a; Garzon and
Pickel, 2001; Svingos et al., 2001; Jhou et al., 2009). Morphine
indirectly excites dopamine neurons via inhibition of these GABA
neurons that synapse on dopaminergic dendrites in the VTA
(Johnson and North, 1992; Jalabert et al., 2011). This disinhibition
of dopamine neurons requires NMDAR and AMPAR activation
(Jalabert et al., 2011). Taken together, the effects of opioids onVTA
function involve a close interaction between postsynaptic MORs
and glutamate signaling.
EFFERENTS
There is a topographical organization to the VTA, with dopamine
and GABAergic efferents having a medial to lateral projection to
output structures such as theNAc, PFC,cingulate cortex, andbaso-
lateral amygdala (Ikemoto, 2007). In addition, there is a rostral
to caudal organization in which the ratio of dopamine to GABA
decreases caudally (Bourdy and Barrot, 2012). In broad terms,
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there are stronger drug reward associations in the caudal-medial
versus anterior VTA (Ikemoto, 2007).
ACUTE OPIOIDS
CLINICAL DESCRIPTION
The National Survey on Drug Use and Health (NSDUH, 2013),
the National Monitoring the Future survey study (Johnston et al.,
2014), and the Columbia CASA report (The National Center
on Addiction and Substance Abuse, Columbia University, 2011)
provide consistently alarming trends of early age initiation of pre-
scription opioid misuse (1.5% of children age 12–13 years old
used in the prior month) and heroin use, with a national average
age of opioid initiation between 22 and 23 years old. Teenagers
report high availability of illicit opioids: 20 and 45% of high
school seniors report it is easy to get heroin and prescription opi-
oids, respectively (Johnston et al., 2014). Teens report using both
to get high and to relieve tension, despite pervasive disapproval
and perceived risk (The National Center on Addiction and Sub-
stance Abuse, Columbia University, 2011). Teens describe being
high on opioids as, “the best feeling ever,” or, “I ﬁnally felt happy,”
which is not different from the self-reported experiences of adult
initiates.
MOR–GLUTAMATE INTERACTIONS IN THE NAc (see Figure 1)
Acute administration of opioids activates MORs and increases
extracellular dopamine in the NAc (Figure 1, yellow ovals; Di
Chiara and Imperato, 1988a). However, dopamine is not neces-
sary for the acute rewarding effects of opiates in non-dependent
animals, as dopamine receptor blockade or 6-hydroxydopamine
(6-OHDA)-mediated dopamine denervation of the NAc does not
prevent heroin self-administration (Pettit et al., 1984; Gerrits and
Van Ree, 1996). Even evidence demonstrating a requirement for
the NAc in opiate reward and reinforcement is equivocal. For
example, mice can learn to self-administer MOR agonists directly
into the NAc (Goeders et al., 1984; David and Cazala, 2000),
and yet intra-NAc morphine fails to produce conditioned place
preferences in rats (Schildein et al., 1998). Lesions or inactiva-
tion of the NAc partially reduce opiate self-administration (Zito
et al., 1985; Dworkin et al., 1988; Alderson et al., 2001), but it is
difﬁcult to interpret the meaning of these data on their own,
since a decrease in the number of drug infusions at a single
drug dose can mean either a decrease or an increase in the rein-
forcing efﬁcacy of a drug (Mello and Negus, 1996). A study
showing that NAc lesions reduced progressive ratio (PR) respond-
ing for morphine in rats (Suto et al., 2011) supports the idea that
the NAc plays a role in the motivation to work for morphine.
Yet direct infusions of MOR antagonists into the NAc actually
increase heroin self-administration (Vaccarino et al., 1985), which
the authors interpret as a decrease in the reinforcing efﬁcacy of
heroin driving increased drug-taking. Thus, the NAc can mod-
ulate opioid reward and drug-taking behavior, but its precise
role is complicated by prior drug experience and method of
administration.
Human imaging studies have generally shown that, in drug-
experienced people, an immediate (i.e., during the “rush”) effect
of opioid administration is an increase in regional cerebral blood
ﬂow in the anterior cingulate cortex, thalamus, and amygdala
(Schlaepfer et al., 1998; Kosel et al., 2008). In contrast, after the
initial “rush” has subsided and the longer lasting euphoric effects
of acute opioids emerge, blood ﬂow tends to be decreased (London
et al., 1990; Denier et al., 2013). This is consistentwith electrophys-
iological and neurochemical ﬁndings in rats, in which systemic
morphine inhibits spontaneous ﬁring of a majority of neurons
in the mPFC (Giacchino and Henriksen, 1996). In many neu-
rons, MOR-mediated inhibition of adenylate cyclase results in
a decrease in cAMP-dependent activation of voltage-dependent
Ih pacemaker currents (Figure 1, GABAergic neurons, Acute
condition; Williams et al., 2001). A decrease in cAMP shifts the
voltage dependence to more negative potentials, making it harder
to depolarize the neuron. MOR activation suppresses basal and
evoked increases in extracellular glutamate in the NAc and dorsal
striatum (Figure 1, glutamate neurons, Acute and Chronic con-
ditions; Desole et al., 1996; Enrico et al., 1998; Sepulveda et al.,
2004). Although the functional consequences of changes in cere-
bral blood ﬂow and cortical activation are not yet known, the
ﬁndings suggest that opioid-induced reward is associated with
decreased cortical activity and potentially decreased glutamatergic
input to downstream NAc MSNs. Despite the evidence for opiate
modulation of glutamate release in the NAc, there is relatively
little data on the role AMPAR and NMDAR play in mediating
the acute rewarding effects of opiates. This is surprising, given
the previously discussed ﬁndings that acute opiates have pro-
found effects on glutamatergic projections to the NAc and that
the activation state of MSNs plays an important role in affect
and emotional responses to stimuli (Roitman et al., 2005; Car-
lezon and Thomas, 2009). One prediction, based on synaptic
scaling (Turrigiano, 2008), is that opiate-induced decreases in
glutamatergic transmission to the NAc would result in increased
surface expression of AMPARs. There are no known studies that
address this prediction directly. Rather, there is evidence that
expression of NMDAR and AMPAR subunits is decreased in the
NAc core 3 days after acute morphine exposure (Jacobs et al.,
2005). Similarly, there is one study that reports a decrease in
surface levels of NAc GluR1 24 h after an acute morphine injec-
tion (Herrold et al., 2013). Unfortunately this time course does
not actually reﬂect the acute rewarding effects of morphine but
may rather reﬂect a state of acute withdrawal (Rothwell et al.,
2012).
Using intracellular recordings from NAc slice preparations, it
has been reported that acute MOR activation depresses NMDA
and non-NMDA (presumably AMPA) excitatory postsynaptic
potentials (EPSPs) in the NAc through a presynaptic mechanism
involving reductions in spike-generated Ca2+ currents (Martin
et al., 1997). A general effect of MOR activation that could account
for this is inhibition of presynaptic voltage-gated Ca2+ channels
(L-, N-, P/Q-, R-) through Gαo–βγ subunits (see Figures 1 and
2, presynaptic glutamatergic neuron, Acute condition; Law et al.,
2000). Although this would predict a decrease in MSN activation,
this study also demonstrated that postsynaptic NMDA currents
were augmented via a protein kinase C (PKC)-dependent mecha-
nism (Figure 1, postsynapticGABAneuron,Acute condition). The
ultimate consequences of these opposing MOR actions are still not
fully understood. A more recent study in awake and behaving rats
showed that a non-contingent injectionof heroin produced a small
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decrease (not signiﬁcant) in extracellular glutamate in the core in
drug-naïve rats (LaLumiere and Kalivas, 2008). Taken together,
the available data suggest that acute opiates decrease glutamate
release in the NAc in non-dependent animals, which is consistent
with the general ﬁnding that decreases in NAc MSN activation are
associated with reward-like states (Carlezon and Thomas, 2009).
MOR–GLUTAMATE INTERACTIONS IN THE VTA (see Figure 2)
An immediate effect of an acute opiate injection is inhibition of
MOR-containing GABAergic neurons (Figure 2, GABAergic neu-
ron, Acute condition) in the RMTg that make strong synaptic
contacts on the soma and dendrites of dopamine neurons and a
subsequent decrease in LTP of these GABAergic synapses (John-
son and North, 1992; Niehaus et al., 2010; Jalabert et al., 2011;
Mazei-Robison et al., 2011). A second immediate effect is a presy-
naptic inhibition of glutamatergic afferents via MOR-mediated,
arachidonic acid-dependent, activation of voltage-sensitive K+
channels (Figure 2, Glutamate neuron, Acute condition; Manzoni
and Williams, 1999). This effect on glutamate release is confusing,
because onewould expectmorphine to produce rapid activation of
dopamine neurons through both inhibition of GABA inputs and
excitation of glutamatergic inputs. In fact, it has been reported
that an opiate-dependent increase in AMPAR activation in the
VTA is required for disinhibition of dopamine neurons (Gysling
and Wang, 1983; Di Chiara and Imperato, 1988a; Jalabert et al.,
2011). Although not fully understood, the issue is likely related to
timing.
An acute response common to most classes of drugs of
abuse, including opiates, is an increase in AMPA transmission
in dopamine neurons measured 24 h after acute administra-
tion of drug (Ungless et al., 2001; Saal et al., 2003; Brown et al.,
2010). This is thought to be due to an increase in surface
expression of AMPARs. Since acute morphine inhibits activity of
glutamatergic afferent neurons (Giacchino and Henriksen, 1996;
Manzoni and Williams, 1999), this observed increase in evoked
AMPA transmission may not immediately translate to increased
excitation of the VTA. Rather, morphine-induced decreases in
glutamate release to the VTA may promote compensatory, postsy-
naptic increases in AMPA signaling that produce LTP at select
synapses. Consistent with this, an increase in surface expres-
sion of GluR1 in the VTA (Figure 2, Dopamine neuron, Acute
condition) has been reported 24 h (Brown et al., 2010), and as
early as 1 h (Lane et al., 2008), after morphine injection. The
mechanism through which morphine increases GluR1 synaptic
insertion and LTP is not fully understood, but is thought to involve
stimulation of dopamine D5 receptors (Figure 2, Dopamine neu-
ron, Acute condition), which belong to the Gαs-coupled D1-like
receptor family (Schilstrom et al., 2006; Brown et al., 2010). D5,
unlike D1, receptors are expressed on dopamine neurons of the
VTA (Weiner et al., 1991; Khan et al., 2000). Thus, morphine-
induced dopamine release can stimulate D5 receptors in the
VTA, which would activate cAMP-dependent processes including
PKA-dependent phosphorylation of GluR1. Phosphorylation of
GluR1 facilitates synaptic insertion and increases synaptic current
(Kessels and Malinow, 2009), providing a potential mechanism for
feed-forward enhancement of morphine’s actions on dopamine
neurons. Consistent with this, overexpressing GluR1AMPAR sub-
units in the VTA sensitizes rats to the locomotor effects of acute
morphine and potentiates morphine-induced conditioned place
preferences (Carlezon et al., 1997). Although GluR1 trafﬁcking
is evident after only one injection of morphine, it is thought
that the cumulative effects of repeated morphine treatment are
necessary for the plasticity in dopamine neuron excitability that
contribute to the development of sensitization (Carlezon and
Nestler, 2002).
A critical role for VTA AMPA and NMDARs in acute opiate
reward has been demonstrated in behavioral studies. Intra-VTA
delivery of an NMDAR or an AMPAR antagonist increased heroin
self-administration in the same manner that decreasing the avail-
able dose of heroin does (Xi and Stein, 2002). This is consistent
with the idea that NMDA and AMPAR activation is necessary for
the acute reinforcing effects of opioids. Intra-VTA blockade of
either NMDAR or AMPAR decreases both the acquisition and
expression of morphine conditioned place preferences (Harris
et al., 2004). Place conditioningdependsuponan associativemem-
ory of the pairing of an affective state (reward or aversion) with
a context. Thus, the role of VTA glutamate transmission in opiate
effects could be to promote associative learning and/or to promote
a rewarding state that has salience as an unconditioned stimulus
in the place conditioning paradigm.
CHRONIC OPIOIDS
CLINICAL DESCRIPTION
Most individuals who are recently opioid-dependent are not fully
aware they are “hooked.” Getting high is still euphoric, and mild
withdrawal symptoms are surprising and manageable. Cognitive
appraisal is, “I can stop if I need to.” Seeking a more intensive high
may lead the individual to change to a route of administration that
produces a more rapid and potent effect (e.g. oral to intranasal,
or intranasal to intravenous), to try a more potent formulation
(switching analgesics or getting a “good batch” of heroin), or to
mixing opioid use with other substances, particularly sedative-
hypnotics.
Opioids can be administered chronically in a number of ways
(steady dosing of extended release painkillers, repeated intermit-
tent abuse, binge-type self-administration, or any combination
of the preceding), which likely inﬂuences the resulting neural
adaptations. As discussed above, an additional consideration in
interpreting data from chronic drug studies is the time point
at which molecular or behavioral measures are taken. Effects
observed 24 h or more after the end of a chronic drug regi-
men may more accurately reﬂect drug withdrawal rather than
chronic effects per se. Furthermore, accumulating evidence sug-
gests that GPCRs (e.g., MOR) modulate synaptic activity on a
timescale that extends well beyond that of initial receptor activa-
tion, resulting in a metaplasticity that can either lower or raise
the threshold for induction of LTP-like processes (Tenorio et al.,
2010).
MOR–GLUTAMATE INTERACTIONS IN THE NAc
Chronic activation of MORs triggers counteradaptions in cAMP
signaling such that adenylate cyclase function is enhanced (Nestler
and Aghajanian, 1997; Williams et al., 2001). The presence of
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chronic opioids masks the effects of increased cAMP, but it
alters how other GPCRs signal through adenylate cyclase. As
one example, chronic morphine increases the inhibitory efﬁcacy
of presynaptic mGluR2/3 receptors on glutamate release in the
NAc (Figure 1, Glutamatergic neuron, Chronic condition; Mar-
tin et al., 1999). This may evolve from an increased functional
connectivity between mGluR2/3 receptors and upregulated cAMP
signaling.
Numerous studies have examined effects of repeated psy-
chostimulants (contingent and non-contingent administration
protocols) onAMPAR-mediated synaptic transmission in the NAc
(Wolf et al., 2004; Luscher, 2013; Pierce and Wolf, 2013). Unfor-
tunately, relatively little is known about effects of chronic opioids.
These types of studies are important, because available research
has shown that cellular and structural consequences of opioids
often differ from those of psychostimulants (Badiani et al., 2011).
Chronic, steady state levels of morphine achieved with subcuta-
neous morphine pellet implants do not change total protein levels
of AMPAR subunits (Chartoff et al., 2006), although this does not
take into account changes in subcellular localization. To address
this, Glass et al. (2008) used immunogold ultrastructural analy-
sis to demonstrate that surface expression of GluR1 subunits is
decreased after chronic morphine treatment (1 h after 14 days
of non-contingent injections; Figure 1, postsynaptic GABA neu-
ron, Chronic condition). This effect was localized to dopamine D1
receptor-expressing neurons in the NAc shell and in all MSN types
in the core. In contrast, a different opiate regimen (1 day after 1
injection/day for 3 days) produced no change in subcellular distri-
bution of either GluR1 or 2 in the NAc (Mickiewicz and Napier,
2011). The mechanisms by which chronic opioids modulate sub-
cellular distribution of AMPAR subunits are not known. However,
given that activation of MORs inhibits adenylate cyclase and cAMP
production, it is possible that the resulting brake on PKA function
leads to decreased P-GluR1Ser845 in the NAc (Figure 1, postsy-
naptic GABA neuron, Chronic condition), which would favor
internalization processes (Song and Huganir, 2002; Mangiavacchi
and Wolf, 2004). This is consistent with formation of LTD, which
requires clathrin-dependent endocytosis of postsynaptic AMPARs
(Brebner et al., 2005).
More is known about the effects of chronic morphine on
NMDAR-mediated synaptic transmission in the NAc compared
to AMPA transmission. As discussed above, acute morphine’s
actions in the NAc include presynaptic inhibition of glutamate
release as well as a postsynaptic potentiation of NMDAR EPSPs via
activation of PKC (Martin et al., 1997). Postsynaptically, chronic
morphine appears to have several effects on NMDARs, including
a decrease in afﬁnity for the co-agonist glycine and a decrease in
the sensitivity of PKC-mediated NMDAR activation. Using dis-
sociated primary cultures of NAc neurons, it was shown that
these effects may be due, in part, to an increase in expression
or function of the NR2A subunit (Figure 1, postsynaptic GABA
neuron, Chronic condition; Martin et al., 2004). In vivo stud-
ies have reported increased protein levels of NR1 and NR2A in
the NAc after chronic morphine (Inoue et al., 2003; Murray et al.,
2007), although a separate study did not detect a change in NR2A
(Bajo et al., 2006). An intriguing possibility for how MORs and
NMDARs interact is described in the opioid pain literature. It
has been reported that MORs and NR1 subunits physically asso-
ciate in the periaqueductal gray (Rodriguez-Munoz et al., 2012).
Although it is not known if this occurs in the NAc or VTA, it
raises the possibility that MORs can have direct effects on gluta-
mate signaling through G protein signaling and/or through direct
interaction.
MOR–GLUTAMATE INTERACTIONS IN THE VTA
Both basal ﬁring rate and burst activity of VTA dopamine neu-
rons are increased after acute, and during chronic, morphine
treatment, resulting in elevated tonic levels of dopamine in the
NAc (Leri et al., 2003; Georges et al., 2006; although see Mazei-
Robison et al., 2011). However, an acute morphine challenge
fails to further increase dopamine neuron activity (Georges et al.,
2006), suggesting tolerance at the level of dopamine neuron
activation. Recently it has been shown that chronic morphine
increases intrinsic excitability of VTA dopamine neurons through
downregulation of K+ channels (Figure 2, Dopamine neuron,
Chronic condition) concomitantly with decreases in dopamine
soma size (Mazei-Robison et al., 2011). Thus, dopamine neu-
rons are more likely to ﬁre, but because of their smaller size
they release less dopamine. Taken together, these data raise the
possibility that not only does chronic morphine maintain its
inhibitory inﬂuence on GABAergic neurons in the VTA and
RMTg, but it also increases the sensitivity of dopamine neu-
rons to excitation (via Ih). Chronic morphine increases total
levels of GluR1 and NMDA NR1 subunits in the VTA (Fitzger-
ald et al., 1996), and ultrastructural analysis showed that surface
GluR1 is increased in dopaminergic and non-dopaminergic neu-
rons of the parabrachial and paranigral VTA (Figure 2, Dopamine
neuron, Chronic condition; Lane et al., 2008). These ﬁndings
could explain, at least in part, how postsynaptic glutamate trans-
mission is augmented with chronic opioid treatment, and they
also demonstrate that normal glutamatergic signaling is fun-
damentally altered. In the presence of morphine, arachidonic
acid-dependent activation of voltage-dependent K+ conductances
continues to reduce glutamate release from afferent terminals
(Manzoni and Williams, 1999). Yet signaling through GluR1
and possibly NR1 subunits on postsynaptic cells is enhanced
(LTP-like; Fitzgerald et al., 1996; Lane et al., 2008), with no
evidence so far of changes in other AMPAR or NMDAR sub-
units.
The effects of these seemingly opposite phenomenaonbehavior
are not well understood, and provide an important area of future
investigation. Given that AMPARs lacking GluR2 subunits and
NMDARs are able to pass Ca2+, the increase in VTA GluR1 and
NR1 likely results in increased Ca2+-mediated signaling (Figure 2,
Dopamine neuron, Chronic condition), which would be expected
to selectively strengthen those synaptic connections that express
elevated GluR1 and NR1. Consistent with this, intra-VTA infusion
of NMDAR or AMPAR antagonists prior to morphine condi-
tioning sessions or prior to tests for morphine conditioned place
preferences blocked the development and expression, respectively,
of place preferences (Popik and Kolasiewicz, 1999; Harris et al.,
2004). These effects appear to be limited to the rostral VTA
(enriched for dopamine neurons), as AMPAR blockade of the cau-
dal VTA (enriched for GABA neurons) had no effect on morphine
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conditioned place preferences (Shabat-Simon et al., 2008). Also,
mice with a global knockout of GluR1 show reduced naloxone-
precipitated withdrawal signs after an escalating dose regimen of
morphine (Vekovischeva et al., 2001). This suggests that GluR1 is
required for full dependence to develop. Consistent with the idea
that increased GluR1 expression in the VTA facilitates dopamine
neuron activation, it was shown that transient over-expression of
GluR1 usingHSV (herpes simplex virus) vectors in the rostralVTA
increased the rewarding effects of a morphine challenge, whereas
GluR overexpression in the caudal VTA had the opposite effect
(Carlezon et al., 2000).
OPIOID WITHDRAWAL
CLINICAL DESCRIPTION
With severe OUD, episodes of opioid withdrawal are more fre-
quent andmore aversive, and getting high gives only brief pleasure,
mostly attributed to cessation of withdrawal. Individuals now use
“to feel normal” and “to be able to function.” Pre-occupation with
obtaining a steady source of opioids is now prevalent, and episodes
of anxiety, irritability, and dysphoria are more frequent. This is a
stage of securing a steady opioid supply through friends, dealers,
or a doctor. This is also the stage when an individual who never
intended to use intravenously converts to injection use.
Forced abstinence is accompanied by severe withdrawal, anx-
iety, dysphoria, and intense, recurrent cravings to use opioids.
Those who cannot access a source become quite desperate to
obtain opioids, and will frequently self-injure in order to receive
opioid analgesia in emergency health care settings. The fear of
being cut off from opioid supply becomes ever-present and moti-
vation to hoard opioid supplies becomes habitual. This may
present as routinely exploring medicine cabinets while visiting
friends and family, and ﬁnding reasons to visit someone during
illness or post-surgical recovery, in hope of surreptitiously taking
narcotic analgesics from them. This may also be a time of criminal
behavior initiation (stealing, prostitution, running goods, etc.) to
support an opioid habit.
Withdrawal from chronic opioids essentially unmasks all the
neural adaptations thebrainproduced in its attempts to equilibrate
in the presence of drug. Consequently, neural circuits regulating
everything from gastrointestinal function to affective states are
instantly unbalanced, and an OWS emerges. A primary cause of
psychological withdrawal signs, which include anxiety, dysphoria,
depression, and irritability, is thought to be the dramatic reduc-
tion in dopamine neuron ﬁring and dopamine release in efferent
targets (Diana et al., 1995). Neural circuits other than the meso-
corticolimbic system also play critical roles in the OWS – both
somatic and psychological. These include norepinephrine (NE;
Weinshenker and Schroeder, 2007), corticotropin releasing factor
(CRF; Contarino and Papaleo, 2005), orexin (Mahler et al., 2012),
dynorphin (Yuferov et al., 2004; Schlosburg et al., 2013), and many
more (for review, see Koob, 2009). It is likely that MOR-induced
neuroplasticity in glutamate transmission underlies – at least in
part – the effects of each of these systems on OWS.
MOR–GLUTAMATE INTERACTIONS IN THE NAc
Spontaneous or naloxone-precipitated withdrawal from chronic
opioids leads to a general increase in neuronal activity and
transmitter release due to the removal of inhibitory MOR tone.
For example, GABA release is increased in the NAc during with-
drawal, particularly after activation of adenylate cyclase (Figure 1,
presynaptic GABA neuron, Withdrawal condition; Chieng and
Williams, 1998). Importantly, the ability of opioids to inhibit
GABA release is also enhanced, suggesting that this may be one
mechanism underlying the irresistible temptation to ﬁght OWS
with opioids themselves. Glutamate release has also been shown
to increase, and numerous studies have shown that systemic or
intracerebroventricular administration of NMDAR or AMPAR
antagonists reduces morphine tolerance and/or withdrawal signs
(Trujillo and Akil, 1991; Tokuyama et al., 1996; Gonzalez et al.,
1997). Much less is known about the speciﬁc role of NAc glu-
tamate transmission in the OWS. Extracellular glutamate levels
are signiﬁcantly increased in the NAc during morphine with-
drawal (Figure 1, presynaptic Glutamatergic neuron, Withdrawal
condition; Aghajanian et al., 1994; Desole et al., 1996; Sepul-
veda et al., 1998, 2004), although increased extracellular glutamate
does not necessarily mean that excitatory synaptic transmission
is increased (Kalivas, 2009). For example, it has been shown
that presynaptic mGluR2/3 inhibitory autoreceptor function is
increased during morphine withdrawal (Figure 1, presynaptic
Glutamatergic neuron, Withdrawal condition) and mGluR2/3
receptor agonists attenuate behavioral signs of morphine with-
drawal (Robbe et al., 2002b) and context-induced reinstatement
of heroin seeking (Bossert et al., 2006). These ﬁndings support
the idea that, although glutamate levels are increased, synap-
tic transmission may be decreased during withdrawal. Thus,
it is not yet clear how the combination of chronic morphine-
induced increases in AMPAR and NMDAR subunit expression,
withdrawal-induced increases in extracellular glutamate, and
increased autoinhibition of cortical afferents is synthesized into
behavioral output.
Understanding the molecular mechanisms by which increased
extracellular glutamate and AMPAR and NMDAR in the NAc
contribute to OWS will be key to understanding and prevent-
ing relapse. As one example, the mechanism by which presynaptic
mGluR2/3 receptor function is augmented is not known. Under
normal conditions, these Gαi-coupled receptors inhibit evoked
glutamate release by P/Q Ca2+ channel inhibition and PKA-
dependent mechanisms (Robbe et al., 2002a). Chronic morphine
and withdrawal has no effect on these processes in the NAc, rais-
ing the possibility of MOR-induced novel signaling mechanisms
(Robbe et al., 2002b). In a second example, Shen et al. (2011)
showed that 2 weeks of extinction following 2 weeks of daily
heroin self-administration resulted in thinner dendritic spines
in the NAc concomitant with an increase in surface expression
of NR2B subunits (Figure 1, postsynaptic GABA neuron, With-
drawal condition). Consequently, overall synaptic strength was
unchanged, but the AMPA/NMDA ratio (a proxy for synaptic
plasticity) was decreased due to increased NMDA current with
no change in AMPA current. What this means for the OWS was
not investigated in this study, but Shen et al. (2011) found that the
heroin withdrawal-induced increase in surface NR2B was neces-
sary for heroin- and cue-induced reinstatement of heroin seeking.
A heroin prime given to rats in which heroin seeking had been
extinguished resulted in a rapid increase in spine density and
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synaptic strength. This group concluded that increased NR2B
formed silent synapses in PFC to NAc core connections such that a
reinstatement trigger enabled synapses to rapidly develop an LTP-
like increase in ﬁeld-potential strength necessary for resumption
of heroin seeking. Based on prior studies of how silent synapses
are “unsilenced” it is likely that Ca2+-induced Ca2+/calmodulin-
dependent protein kinase II (CaMKII) facilitates shuttling of
AMPARs from extrasynaptic sites on the plasma membrane to
synaptic zones (Kerchner and Nicoll, 2008). In a different study,
NR2A knockout mice treated chronically with morphine show
reduced somatic withdrawal signs (Inoue et al., 2003). Restora-
tion of NR2A expression selectively in the NAc allowed for the
expression of somatic withdrawal signs. The NAc is not usu-
ally perceived as a substrate for somatic withdrawal, but this and
other studies (Harris and Aston-Jones, 1994; Chartoff et al., 2009)
indicate that it is a necessary – and perhaps even sufﬁcient –
component.
Morphine dependence andwithdrawalmay lower the threshold
for LTP-like processes through a cAMP mechanism. Acute stim-
ulation of Gαi-coupled MORs leads to a decrease in cAMP levels
(Childers, 1991). In the presence of chronic morphine, however,
molecular adaptations occur such that adenylate cyclase activ-
ity increases and cAMP levels return to approximately normal;
when morphine is discontinued or the opioid receptor antago-
nist naloxone is administered, cAMP levels dramatically increase
(for review, see Nestler and Aghajanian, 1997). Previously we have
shown that naloxone-precipitated withdrawal increases levels of
phosphorylated CREB (P-CREB) and P-GluR1Ser845 in the NAc of
morphine-dependent rats (Figure 3A; Chartoff et al., 2006). Using
primary cultures of dissociated striatal neurons, we demonstrated
that administration of naloxone to cultures treated chronically
with morphine enabled the dopamine D1 receptor agonist SKF
82958 to super-induce P-GluR1Ser845, an effect blocked by the
selective PKA inhibitor, H89 (Figure 3B). Together, these data
predict that surface expression (although not necessarily synap-
tic expression) of GluR1 subunits would increase during opioid
withdrawal. This has not been directly tested, although it has
been shown that targeted overexpression of GluR1 (but not
GluR2) in the NAc produces anhedonia in the intracranial self-
stimulation paradigm (Todtenkopf et al., 2006). One caveat may
be that withdrawal-induced increases in extracellular glutamate
trigger internalization/desensitization of AMPARs – reminiscent
of synaptic scaling (Turrigiano, 2008). These predictions are
not mutually exclusive, as glutamate-triggered desensitization
would likely be a pan-NAc effect whereas PKA-mediated P-
GluR1Ser845 and membrane insertion would likely occur only in
MOR-expressing neurons.
As discussed in the beginning of this review, acute and pro-
tracted OWS has been shown clinically to precipitate relapse.
Using an animal model of relapse, several studies have shown
that glutamate release and AMPAR activation in the NAc core
are necessary for reinstatement of heroin seeking after a period
of withdrawal in which operant responding for heroin is extin-
guished (Bossert et al., 2006, 2011, 2012; LaLumiere and Kalivas,
2008). These studies raise an important issue – namely whether
a heroin prime or a heroin-associated context (used as trig-
gers for reinstatement) produces a negative affective state akin
to OWS or a drug-like rewarding state that drives reinstate-
ment. Increasing evidence supports the former: activation of
NAc neurons (i.e., via glutamatergic transmission) is associated
with aversive states (Carlezon and Thomas, 2009). The relevance
of this hypothesis to heroin reinstatement studies remains to be
tested.
MOR–GLUTAMATE INTERACTIONS IN THE VTA
During morphine withdrawal GABA release is increased due
to MOR-induced upregulation of cAMP signaling (Figure 2,
GABAergic neuron, Withdrawal condition; Bonci and Williams,
1996, 1997), and glutamate release is decreased due to an increase
in thepotencyof GABAB receptor andmGluR-mediatedpresynap-
tic inhibition (Figure 2, Glutamate neuron,Withdrawal condition;
Manzoni and Williams, 1999). Combined, these effects lead to a
strong suppression of dopamine neuron activation (Diana et al.,
1995). Interestingly, it has been found that chronic morphine’s
almost ubiquitous upregulation of adenylate cyclase does not play
a role in modulation of glutamate release in the VTA during
withdrawal (Manzoni and Williams, 1999) leaving the mecha-
nism for augmented inhibition of glutamate release unknown
for now.
One confusing aspect of MOR–glutamate interactions in the
VTA during opioid withdrawal is that the actual time course of
withdrawal-induced effects on glutamatergic neurotransmission is
not known. Putting together available data, the immediate effect of
withdrawal is relief of MOR-mediated inhibition of glutamatergic
and GABAergic afferents to dopamine neurons and an increase
in glutamate and GABA release. Subsequently, glutamate and
GABA engage the more slowly acting metabotropic mGluR2/3
and GABAB receptors on glutamatergic terminals resulting in
decreased glutamatergic synaptic transmission (Figure 2, Glu-
tamate neuron, Withdrawal condition). The complexity of this
scenario raises the possibility that plasticity within micro-regions
containing MOR-expressing GABA and glutamate terminals that
synapse onto dopamine neurons results in ﬁne temporal and
spatial control over synaptic communication. How this affects
NMDAR and AMPAR function is not known, although one
prediction is thatAMPARs get promoted to synapseswithinmicro-
regions in which glutamate release is decreased and removed from
synapses in which glutamate release is increased. This selective
strengthening of synapses could provide a mechanism for associa-
tive learning that occurs with conditioned withdrawal (Myers and
Carlezon, 2010b).
RELAPSE
CLINICAL DESCRIPTION
In humans, the risk for relapse decreases the longer a person
remains abstinent. This is thought to be due, in part, to the fact that
the most powerful motivation to relapse stems from the desire to
alleviate the initial physiological withdrawal. Opioid agonist ther-
apies are extremely successful in treating this phase of the OWS.
Unfortunately, withdrawal from these medications also produces
withdrawal signs that can trigger relapse. Furthermore, they do
not treat other facets of abstinence, including cue reactivity.
Abstinent addicts are at high risk for relapse due to conditioned
craving and withdrawal elicited by previously drug-paired cues
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(Wikler, 1973; O’Brien et al., 1986). In fact, heroin addicts report
that the temptation or urge to use drug is elicited most powerfully
by drug-paired cues (Heather et al., 1991). Incentive salience is
the term that describes the unconscious and hypervigilant focus
on rapid identiﬁcation of any environmental cues that predict
access to opioid using. During early recovery treatment, patients
are taught to avoid high-risk “people, places, and things” to pre-
vent cue-conditioned relapse. However, they are often bafﬂed by
their inability to reliably detect and avoid such triggers. This is
because incentive salience is not a learned association within con-
scious awareness. A common clinical example would be that of an
abstinent opioid addict being drawn to a person who is actively
using while not recognizing that behavioral cues associated with
that person’s drug use, and not his/her personality, are the source
of interpersonal interest. On a positive note, cue reactivity wanes
with time, and it appears as if the success of abstinence itself begins
to provide a protective factor against relapse (see Epstein et al.,
2006).
MORPHINE–GLUTAMATE INTERACTIONS IN THE NAc
The majority of studies examining the role of NAc glutamater-
gic transmission in animal models of opioid relapse utilize the
reinstatement model of drug seeking, in which the operant
behavior producing contingent opioid administration is extin-
guished over time and then reinstated with non-contingent drug,
cue, or stress presentation (Shalev et al., 2002). There is lit-
tle data on how glutamatergic transmission regulates negative
reinforcement mechanisms stemming from OWS. In a seminal
study, LaLumiere and Kalivas (2008) demonstrated in rats that a
non-contingent heroin prime or discrete cues previously paired
with heroin infusions increased extracellular glutamate in the
NAc core via increased synaptic transmission from PFC affer-
ents. Intra-NAc core AMPAR blockade prevented reinstatement
of heroin seeking. A separate study showed that microinjec-
tions of the mGluR2/3 receptor agonist LY379268 into the NAc
shell, which inhibits evoked glutamate release from cortical affer-
ents, reduced context-induced reinstatement of heroin seeking
(Bossert et al., 2006). Interestingly, this group proposed that the
reduction in heroin seeking was due to decreases in the motiva-
tional signiﬁcance of the heroin context rather than to interference
with memory retrieval. This is consistent with the idea that incen-
tive salience underlies the power of a drug-paired cue to evoke
drug-seeking behavior, and raises the possibility that heroin-
associated cues increase synaptic glutamate release in the NAc
thus producing an aversive state (Carlezon and Thomas, 2009;
although see Stewart et al., 1984). Finally, chronic heroin self-
administration increases NR2B subunits in the NAc (see Chronic
Opioids). This is necessary for a heroin prime-induced increase
in synaptic strength, dendritic spine enlargement, and reinstate-
ment of heroin seeking after a period of extinction (Shen et al.,
2011).
Although the VTA has been implicated in conditioned and
unconditioned reinforcing effects of opioids (Stewart et al., 1984),
and intra-VTAmicroinjections of themGluR2/3 agonist LY379268
partially alleviate context-induced reinstatement of heroin seek-
ing (Bossert et al., 2004), there is relatively little data on VTA
glutamatergic transmission and relapse.
IMPLICATIONS FOR MEDICATIONS DEVELOPMENT
Opioid dependence and withdrawal disrupts excitatory neuro-
transmission in reward-related brain circuits, which contributes
to negative affective states associated with OWS and to corrup-
tion of motivated behavior away from natural rewards toward
obtaining and taking drug. Efforts are underway to develop phar-
macotherapies that target these aspects of addiction, but there
has not been a major advancement in treatment options. Given
what is known about the effects of MOR activation on glutamater-
gic transmission within the mesolimbic dopamine system, some
ideas for targets emerge (see Figures 1 and 2).
• Extracellular glutamate levels are increased in NAc and VTA
during opioid withdrawal.
• NMDAR levels/function is increased in both the NAc andVTA
with chronic opioids.
• MOR-expressing neurons become hyperexcitable with opioid
withdrawal.
• GluR1 AMPAR subunits decrease in NAc and increase in VTA
with chronic opioids.
Some compounds that act on these targets and have shown
some promise in the treatment of addiction include:
• Topiramate/Lamotrigine – Used therapeutically as anticonvul-
sants and mood stabilizers. Mechanisms of action include
inhibition of voltage-gatedNa+ andCa2+ channels and activa-
tion of GABAA receptors (Rogawski and Loscher, 2004). May
also block GluR5-containing AMPARs. Showed some promise
as an adjunct during detoxiﬁcation in a small study (Zullino
et al., 2004).
• Lacosamide –Used therapeutically as an anticonvulsant. Mech-
anismof action is to enhance slow inactivation of voltage-gated
Na+ channels (Beyreuther et al., 2007). Reduces the reward-
related effects of cocaine at doses that do not impact motor
capacity (Beguin et al., 2012).
• Memantine – Used to treat cognitive decline in Alzheimer’s
patients. Primary mechanism of action is as a noncompet-
itive NMDAR antagonist. Reduced expression of naloxone-
precipitated physical withdrawal signs in heroin-dependent
patients (Bisaga et al., 2001).
None of these compounds have demonstrated remarkable
effects, indicating that speciﬁcally targeting glutamate transmis-
sion will not be a panacea for opioid addiction. Notably none have
been tested on protracted withdrawal signs such as anxiety and
depression or on conditioned withdrawal or craving.
CONCLUSION
Mu opioid receptor agonists such as morphine and heroin per-
turb the delicate balance of neurophysiological communication
maintained by endogenous opioid peptides in the brain. The fact
that a heroin “rush” or naloxone-precipitated withdrawal signs in
opiate-dependent individuals can be felt within seconds of intra-
venous injection is evidence that the onset and offset of MOR
activation can have rapid effects on cellular activity. The fact that
some people develop a loss of control over opiate intake such
that they engage in compulsive drug taking behaviors – despite
severe negative consequences – is evidence that activation of MOR-
coupled G proteins can have slower effects to alter neural circuits
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regulating motivated behavior. And the fact that drug-associated
cues or contexts trigger relapse at some point in almost all opiate
addicts trying to stay abstinent is evidence that activation of MOR-
coupled G proteins facilitates long-lasting synaptic plasticity that
maintains drug-related memories. As discussed in this review, this
constellation of MOR effects stems in a large part from crosstalk
between MOR-associated G protein signaling and glutamatergic
neurotransmission.
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